Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
Microba Life Sciences (ASX:MAP), a microbiome testing company, rallied on strong volume growth. In July 2026, Perennial reported Microba rose 33% after a positive quarterly update, with testing volumes delivering another period of quarter-on-quarter growth. Microba Life Sciences operates in the Healthcare sector within the Healthcare Providers and Services industry, and Thesis Tracker has captured 1 comment from 1 fund manager, Perennial Partners. Headquartered in Brisbane, Microba provides microbiome testing and analysis services, including its MetaXplore gastrointestinal tests for clinicians, and develops pathology services, supplements and microbiome-based therapeutics for conditions such as inflammatory bowel disease, serving customers in Australia, the UK and the US, and is expanding its clinical testing business while advancing drug development programs.
Company figures as of 15 Oct 2026. For information only.
Fund managers including Perennial Partners have invested in Microba Life Sciences Ltd (ASX:MAP).
Perennial highlights continued growth in testing volumes, which drove a 33% share price rise.
The available commentary does not detail specific risks, though Microba must convert test volume growth into profitability.
Microba Life Sciences Ltd. (Brisbane, Australia) provides microbiome testing, supplements, and analysis services, and develops pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company operates through two segments: Testing Services and Supplements, and Research and Development. Founded on January 31, 2017 by Gene Tyson and Philip Hugenholtz, Microba focuses on gut microbiome science to support diagnostic and therapeutic innovation. Its offerings span consumer and clinical microbiome testing alongside ongoing research into microbiome-based health solutions.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.